Search results for " Cancer"
showing 10 items of 6120 documents
Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older Women in Germany and the United States
2020
Background: Breast cancer treatment has changed tremendously over the last decades. In addition, the use of mammography screening for early detection has increased strongly. To evaluate the impact of these developments, long-term trends in incidence, mortality, stage distribution and survival were investigated for Germany and the United States (US). Methods: Using population-based cancer registry data, long-term incidence and mortality trends (1975&ndash
Survival trends for primary liver cancer, 1995–2009: analysis of individual data for 578,740 patients from 187 population-based registries in 36 coun…
2019
CONCORD Working Group Members: Africa—Algeria: S Bouzbid (Registre du Cancer d’Annaba); M Hamdi-Chérif*, Z Zaidi (Registre du Cancer de Sétif); Gambia: R Swaminathan (National Cancer Registry); Lesotho: SH Nortje (Children’s Haematology Oncology Clinics - Lesotho); Libya: MM El Mistiri (Benghazi Cancer Registry); Mali: S Bayo, B Malle (Kankou Moussa University); Mauritius: SS Manraj, R Sewpaul-Sungkur (Mauritius National Cancer Registry); Nigeria: A Fabowale, OJ Ogunbiyi* (Ibadan Cancer Registry); South Africa: D Bradshaw, NIM Somdyala (Eastern Cape Province Cancer Registry); DC Stefan (Umtata University); Tunisia: L Jaidane, M Mokni (Registre du Cancer du Centre Tunisien). America (Central…
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitab…
2007
The synergistic effect exerted by the HDAC inhibitor SAHA and the sesquiterpene lactone parthenolide on triple negative breast canc er cells
2014
Triple-negative breast cancer (TNBC) is a subtype o f breast cancer, insensitive to endocrine therapy. Chemotherapy is the main form of treatment, but is accompanied by a high rate of recidivism. The sesquiterpene lactone Parthenolide (PN) exerts a cy totoxic effect on MDA-MB231 cells, a TNBC cell line (1), but was ineffective at low doses (2-5μM). This repr esents an obstacle for a therapeutic utilization of PN. We supposed, in line with other authors (2), that PN c auses a protective response, which at low doses pre vails on the cytotoxic effect. With the aim of inhibiting this protective effect we have shown that pre-trea tment of MDA-MB231 cells with SAHA (2-5μM), an histone deace tylat…
Trombocitozes saistība ar ne-sīkšūnu plaušu vēža pacientu demogrāfiskajiem un klīniskajiem faktoriem
2019
Ievads. Lai gan tiek izstrādātas arvien efektīvākas ļaundabīgo audzēju agrīnas skrīninga un diagnostikas metodes, ne-sīkšūnu plaušu vēzis vēl joprojām pārsvarā tiek atklāts III vai IV stadijā, līdz ar to tas ir viens no vadošajiem audzējiem mirstības ziņā. Trombocīti piedalās vēža šūnu augšanā un tālākā izplatīšanā pa organismu. Ne-sīkšūnu plaušu vēža pacientiem bieži ir palielināts trombocītu skaits, kas ir saistīts ar sliktu prognozi. Tamdēļ, ir būtiski noskaidrot vai pastāv kādi ne-sīkšūnu plauša vēža pacienta demogrāfiskie vai klīniskie rādītāji, kam ir korelācija ar trombocitozi. Tas ļautu laicīgi paredzēt to, ka pacientam iespējams būs palielināts trombocītu skaits un izrietoši sliktā…
Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments
2021
Muscle wasting, i.e., cachexia, frequently occurs in cancer and associates with poor prognosis and increased morbidity and mortality. Anticancer treatments have also been shown to contribute to sustainment or exacerbation of cachexia, thus affecting quality of life and overall survival in cancer patients. Pre-clinical studies have shown that blocking activin receptor type 2 (ACVR2) or its ligands and their downstream signaling can preserve muscle mass in rodents bearing experimental cancers, as well as in chemotherapy-treated animals. In tumor-bearing mice, the prevention of skeletal and respiratory muscle wasting was also associated with improved survival. However, the definitive proof tha…
Extracellular Vesicles as Shuttles of Tumor Biomarkers and Anti-Tumor Drugs
2014
Extracellular vesicles (EV) include vesicles released by either normal or tumor cells. EV may exceed the nanometric scale (microvesicles), or to be within the nanoscale, also called exosomes. Thus, it appears that only exosomes and larger vesicles may have the size for potential applications in nanomedicine, in either disease diagnosis or therapy. This is of particular interest for research in cancer, also because the vast majority of existing data on EV are coming from pre-clinical and clinical oncology. We know that the microenvironmental features of cancer may favor cell-to-cell paracrine communication through EV, but EV have been purified, characterized, and quantified from plasma of tu…
Urīnizvadceļu agrīno komplikāciju raksturojums pacientiem pēc taisnās zarnas vēža rezekcijas
2018
Mūsdienu klīniskajā medicīnā taisnās zarnas vēzis ir viena no nopietnām problēmām. Taisnās zarnas vēža ārstēšana balstās, galvenokārt, uz ķirurģiskās operācijas, kas, neskatoties uz visu mūsdienas medicīnas attīstību, var novest pie vairākām komplikācijām. Starp visiem pēcoperācijas traucējumiem vienu no vietām aizņem urīna izvadceļu komplikācijas. Zinātniskajos avotos ir aprakstīts, ka pētāmā problēma ir sastopamā 5-88% gadījumos, vīdēji 27% gadījumos, kas ir ļoti būtiski. Minētā tēma ir pētīta no pagājušā gadsimta, bet neskatoties uz lielu un aktīvo zinātnisko interesi, arī šodien pastāv dažādi un dažreiz pretrunīgi viedokļi un atšķirīgi dati par faktoriem, kas ietekmē pēcoperācijas urīna…
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus
2019
Background. Management of venous thromboembolism (VTE) in patients with haematologic malignancies and thrombocytopenia is clinically challenging due to the related risks. No prospective studies or clinical trials have been carried out and, therefore, no solid evidence on this compelling issue is available. Methods. Given this, an expert panel endorsed by the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on Thrombosis and Haemostasis was set up to produce a formal consensus, according to the RAND method, in order to issue clinical recommendations about the platelet (PLT) cut-off for safe administration of low molecular weight heparin (LMWH) in thrombocytopenic (PLT <100×…